A retrospective study to investigate that neutrophil to lymphocyte ratio is useful to predict the prognosis of advanced gastric cancer patients treated with Paclitaxel and Ramucirumab

Trial Profile

A retrospective study to investigate that neutrophil to lymphocyte ratio is useful to predict the prognosis of advanced gastric cancer patients treated with Paclitaxel and Ramucirumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Paclitaxel (Primary) ; Ramucirumab (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 New trial record
    • 09 May 2017 Results presented at the Digestive Disease Week 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top